Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00839956 · ClinicalTrials.gov registry record · Phase 2

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

A Phase 2 study of DS Stage I Plasma Cell Myeloma and DS Stage II Plasma Cell Myeloma, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
Phase 2
Development phase
31
Enrollment target
1
Study location

NCT00839956 is a Phase 2 study of DS Stage I Plasma Cell Myeloma and DS Stage II Plasma Cell Myeloma that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 31 participants, below the 59-participant average among 5 other DS Stage I Plasma Cell Myeloma trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00839956, a Phase 2 study of DS Stage I Plasma Cell Myeloma and DS Stage II Plasma Cell Myeloma, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the side effects of giving bortezomib together with vorinostat and to see how well it works in treating patients with multiple myeloma who have undergone autologous stem cell transplant. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat after an autologous stem cell transplant may stop the growth of any cancer cells that remain after transplant.

Conditions Studied

DS Stage I Plasma Cell Myeloma DS Stage II Plasma Cell Myeloma DS Stage III Plasma Cell Myeloma

Interventions

  • DRUG Bortezomib
  • DRUG Vorinostat

Study Locations (1)

Washington

  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2009-02
Est. Completion 2017-03-31
Phase Phase 2

Sponsor

Fred Hutchinson Cancer Center

483 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00839956

The ClinicalTrials.gov registry entry for NCT00839956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 59-participant average among 5 other DS Stage I Plasma Cell Myeloma trials with a reported enrollment target (47% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with DS Stage I Plasma Cell Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Bortezomib is the first listed.

NCT00839956 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00839956 about?

NCT00839956 is a clinical study titled "Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant". This phase II trial studies the side effects of giving bortezomib together with vorinostat and to see how well it works in treating patients with multiple myeloma who have undergone autologous stem cell transplant. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the...

What is the current status of trial NCT00839956?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2009-02. Estimated completion is 2017-03-31.

What conditions does trial NCT00839956 study?

This clinical trial studies the following conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma.

What interventions are being tested in trial NCT00839956?

The interventions under investigation include: Bortezomib (DRUG), Vorinostat (DRUG).

Who is sponsoring clinical trial NCT00839956?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00839956 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for DS Stage I Plasma Cell Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

DS Stage I Plasma Cell Myeloma

All registered trials for this condition

DS Stage II Plasma Cell Myeloma

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.